Back
Compare AU
Compare ATOM vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X Uranium ETF (ATOM) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
ATOM | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 138 | 74 |
Median incremental investment | $1,000.00 | $742.79 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,747.20 | $1,924.16 |
Average age group | > 35 | > 35 |
Key Summary
ATOM | DRUG | |
|---|---|---|
Strategy | ATOM.AX was created on 2022-12-07 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Global Uranium & Nuclear Components Total Return Index | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Cameco Corp (23.21 %) NexGen Energy Ltd (6.28 %) Oklo Inc Class A Shares (6.23 %) | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Energy (57.48 %) Utilities (16.32 %) Industrials (11.79 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | Canada (41.16 %) United States (28.35 %) Korea (8.72 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0.69 % | 0.57 % |
Key Summary
ATOM | DRUG | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | Solactive Global Uranium & Nuclear Components Index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.69 % | 0.57 % |
Price | $18.20 | $8.59 |
Size | $120.415 million | $209.051 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 3.55 % | 1.82 % |
Market | ASX | ASX |
First listed date | 06/12/2022 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ATOM | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 138 | 74 |
Median incremental investment | $1,000.00 | $742.79 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,747.20 | $1,924.16 |
Average age group | > 35 | > 35 |
Pros and Cons
ATOM | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ATOM | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |